Disease intelligence · mutation landscape
Follicular lymphoma mutation landscape
How often each gene is altered in follicular lymphoma, in each sequenced cohort, over the patients on whom it could have been called. Copy number is its own row. Nothing is pooled.
Answer block
In MSK-IMPACT Heme, follicular lymphoma subset (2022) (193 sequenced patients, targeted panel), the most frequently altered of the 45 genes shown are CREBBP 70.98%, KMT2D 66.32%, TNFRSF14 46.63%, BCL2 34.72%, EZH2 20.73%. Each figure divides by the patients on whom that gene could be called.
Of the briefing's 12 curated targets, 1 are altered in under 2% of this cohort (CD79B): targets by expression, dependency or drug label, not by mutation. Frequency is not targetability, in either direction.
1 cohorts are shown and none are pooled; overlap between them has not been checked and there is no disease-wide percentage.
Evidence boundary: frequency here is a count in a named cohort. Whether an alteration is a driver, is actionable, or has a drug is the briefing's question and is not inferred from these numbers.
What is altered, by cohort
One row per alteration, not per gene: a gene that is amplified and rarely mutated (ERBB2, MYCN, EGFR) gets a row for each. Every cell divides by its own denominator — the patients in that cohort on whom that gene could be called. Copy-number rows are shown only where at least one cohort reaches 2%.
| Alteration | heme_msk_impact_2022 193 pts · targeted panel |
|---|---|
| BCL2 SNV / small indel | 34.72%67/193 |
| MS4A1 SNV / small indel | · |
| CD19 SNV / small indel | · |
| EZH2 SNV / small indel | 20.73%40/193 |
| CREBBP SNV / small indel | 70.98%137/193 |
| CREBBP deep deletion | 2.07%4/193 |
| KMT2D SNV / small indel | 66.32%128/193 |
| CD79B SNV / small indel | 1.55%3/193 |
| PIK3CD SNV / small indel | · |
| BTK SNV / small indel | 6.22%12/193 |
| CD22 SNV / small indel | · |
| TNFRSF14 SNV / small indel | 46.63%90/193 |
| TNFRSF14 deep deletion | 11.4%22/193 |
| STAT6 SNV / small indel | 20.21%39/193 |
| FOXO1 SNV / small indel | 18.13%35/193 |
| SOCS1 SNV / small indel | 15.54%30/193 |
| SOCS1 deep deletion | 2.07%4/193 |
| H1-4 SNV / small indel | 15.54%30/193 |
| IRF8 SNV / small indel | 15.03%29/193 |
| ARID1A SNV / small indel | 13.47%26/193 |
| MEF2B SNV / small indel | 11.92%23/193 |
| EP300 SNV / small indel | 10.88%21/193 |
| CARD11 SNV / small indel | 10.88%21/193 |
| TNFAIP3 SNV / small indel | 10.36%20/193 |
| TNFAIP3 deep deletion | 5.18%10/193 |
| GNA13 SNV / small indel | 9.84%19/193 |
| TP53 SNV / small indel | 9.33%18/193 |
| RRAGC SNV / small indel | 9.33%18/193 |
| ATP6V1B2 SNV / small indel | 8.29%16/193 |
| BCR SNV / small indel | 7.77%15/193 |
| SGK1 SNV / small indel | 7.25%14/193 |
| PIM1 SNV / small indel | 7.25%14/193 |
| SRSF2 SNV / small indel | 6.74%13/193 |
| SETD1B SNV / small indel | 6.74%13/193 |
| H1-2 SNV / small indel | 6.74%13/193 |
| LTB SNV / small indel | 6.22%12/193 |
| CCND3 SNV / small indel | 6.22%12/193 |
| B2M SNV / small indel | 6.22%12/193 |
| ACTG1 SNV / small indel | 6.22%12/193 |
| FAT1 SNV / small indel | 5.7%11/193 |
| FAS SNV / small indel | 5.7%11/193 |
| FAS deep deletion | 3.11%6/193 |
| DTX1 SNV / small indel | 5.18%10/193 |
| BTG1 SNV / small indel | 4.66%9/193 |
| HLA-A SNV / small indel | 4.15%8/193 |
| H1-5 SNV / small indel | 4.15%8/193 |
| H1-3 SNV / small indel | 4.15%8/193 |
| EPHA5 SNV / small indel | 4.15%8/193 |
| ATP6AP1 SNV / small indel | 3.63%7/193 |
| ARID5B SNV / small indel | 3.63%7/193 |
observed — shade scales with frequency, full at 30% assayed, none found not on this cohort's panel cohort not readable
Key findings
CREBBP is mutated in 137 of 193 patients in MSK-IMPACT Heme, follicular lymphoma subset (2022).
KMT2D is mutated in 128 of 193 patients in MSK-IMPACT Heme, follicular lymphoma subset (2022).
TNFRSF14 is mutated in 90 of 193 patients in MSK-IMPACT Heme, follicular lymphoma subset (2022).
Gene table — reference cohort
Headline values are from the reference cohort, heme_msk_impact_2022; the matrix above keeps every cohort separate. "Curated" marks a gene the disease briefing lists as a target; the rest are here because they are among the most frequently mutated genes in the reference cohort. Recurrent changes are the reference cohort's commonest protein changes.
FDA biomarker marks a gene the FDA recognises as a biomarker of response to an approved drug; FDA, tumour-agnostic marks the five that apply whatever the primary site. Hover for the drug, the tumour type and the year. This is level 1 only, United States only, and frozen at November 2022 — a dash means the gene was not FDA-recognised on that date, not that it is undruggable, and not that no trial exists. The frequency beside it is how often the gene is altered in this disease, which is a different question from whether these patients are eligible for the drug. Source: Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer. Cancer Discovery 2024;14(1):49-65. doi:10.1158/2159-8290.CD-23-0467, Table 1
| Gene | FDA status | Why listed | Largest alteration | Altered / tested | Frequency | Without hypermutated | Cohorts observed | Range across cohorts | Recurrent changes |
|---|---|---|---|---|---|---|---|---|---|
| BCL2 | — | curated target | SNV / small indel | 67 / 193 | 34.72% | — | 1 / 1 | 34.72–34.72% | A60V (n=6), A131V (n=6), G47D (n=5), P53S (n=5), A131D (n=3) |
| MS4A1 | — | curated target | SNV / small indel | 0 / null | 0.0% | — | 0 / 1 | null–null% | none recurrent |
| CD19 | — | curated target | SNV / small indel | 0 / null | 0.0% | — | 0 / 1 | null–null% | none recurrent |
| EZH2 | FDA biomarker2020 · 1 drug | curated target | SNV / small indel | 40 / 193 | 20.73% | — | 1 / 1 | 20.73–20.73% | Y646F (n=14), Y646N (n=13), A692V (n=5), Y646H (n=4), A682G (n=3) |
| CREBBP | — | curated target | SNV / small indel | 137 / 193 | 70.98% | — | 1 / 1 | 70.98–70.98% | S1680del (n=20), R1446H (n=12), R1446C (n=10), D1435N (n=4), Y1503D (n=4) |
| KMT2D | — | curated target | SNV / small indel | 128 / 193 | 66.32% | — | 1 / 1 | 66.32–66.32% | S2910Rfs*32 (n=5), L1461Tfs*30 (n=3), Q4347Rfs*24 (n=3), L860Rfs*70 (n=3), X1303_splice (n=3) |
| CD79B | — | curated target | SNV / small indel | 3 / 193 | 1.55% | — | 1 / 1 | 1.55–1.55% | T205Sfs*6 (n=1), I175Mfs*28 (n=1), Y197D (n=1) |
| PIK3CD | — | curated target | SNV / small indel | 0 / null | 0.0% | — | 0 / 1 | null–null% | none recurrent |
| BTK | — | curated target | SNV / small indel | 12 / 193 | 6.22% | — | 1 / 1 | 6.22–6.22% | T316Sfs*6 (n=2), E301del (n=1), Y545D (n=1), G50D (n=1), R28G (n=1) |
| CD22 | — | curated target | SNV / small indel | 0 / null | 0.0% | — | 0 / 1 | null–null% | none recurrent |
| TNFRSF14 | — | curated target | SNV / small indel | 90 / 193 | 46.63% | — | 1 / 1 | 46.63–46.63% | W12* (n=14), X102_splice (n=7), M1? (n=4), X23_splice (n=3), G60D (n=3) |
| STAT6 | — | curated target | SNV / small indel | 39 / 193 | 20.21% | — | 1 / 1 | 20.21–20.21% | D419G (n=13), E377K (n=6), D419N (n=5), D419H (n=4), E372K (n=3) |
| FOXO1 | — | by frequency | SNV / small indel | 35 / 193 | 18.13% | — | 1 / 1 | 18.13–18.13% | T24I (n=7), S22P (n=6), M1? (n=6), T24A (n=6), S152R (n=4) |
| SOCS1 | — | by frequency | SNV / small indel | 30 / 193 | 15.54% | — | 1 / 1 | 15.54–15.54% | M161_L162delinsKV (n=2), S116N (n=2), A17T (n=2), I126L (n=1), L73R (n=1) |
| H1-4 | — | by frequency | SNV / small indel | 30 / 193 | 15.54% | — | 1 / 1 | 15.54–15.54% | A167V (n=3), A170V (n=2), A123T (n=2), A116V (n=2), A65P (n=2) |
| IRF8 | — | by frequency | SNV / small indel | 29 / 193 | 15.03% | — | 1 / 1 | 15.03–15.03% | S55A (n=3), T80A (n=3), Y23H (n=3), Q392* (n=2), V426D (n=2) |
| ARID1A | — | by frequency | SNV / small indel | 26 / 193 | 13.47% | — | 1 / 1 | 13.47–13.47% | Y195Cfs*48 (n=2), G1137* (n=2), G105Efs*8 (n=2), Q520* (n=1), S1961Rfs*53 (n=1) |
| MEF2B | — | by frequency | SNV / small indel | 23 / 193 | 11.92% | — | 1 / 1 | 11.92–11.92% | D83V (n=5), D83A (n=4), R24Q (n=3), T70R (n=3), Y69H (n=2) |
| EP300 | — | by frequency | SNV / small indel | 21 / 193 | 10.88% | — | 1 / 1 | 10.88–10.88% | Y1467D (n=3), Y1467F (n=3), Y1467N (n=2), G1375R (n=2), Y1446N (n=2) |
| CARD11 | — | by frequency | SNV / small indel | 21 / 193 | 10.88% | — | 1 / 1 | 10.88–10.88% | D357V (n=5), L253P (n=2), S250P (n=2), Q249P (n=2), E134G (n=1) |
| TNFAIP3 | — | by frequency | SNV / small indel | 20 / 193 | 10.36% | — | 1 / 1 | 10.36–10.36% | L324Qfs*7 (n=3), V398Efs*8 (n=2), K96Sfs*14 (n=2), X269_splice (n=2), R136Qfs*3 (n=2) |
| GNA13 | — | by frequency | SNV / small indel | 19 / 193 | 9.84% | — | 1 / 1 | 9.84–9.84% | V98E (n=3), E33D (n=2), M1? (n=2), K94E (n=1), Q67L (n=1) |
| TP53 | — | by frequency | SNV / small indel | 18 / 193 | 9.33% | — | 1 / 1 | 9.33–9.33% | Y234D (n=2), R175H (n=2), R249G (n=1), V274A (n=1), R282W (n=1) |
| RRAGC | — | by frequency | SNV / small indel | 18 / 193 | 9.33% | — | 1 / 1 | 9.33–9.33% | P87L (n=3), G119R (n=3), T90N (n=3), S75F (n=1), D116H (n=1) |
| ATP6V1B2 | — | by frequency | SNV / small indel | 16 / 193 | 8.29% | — | 1 / 1 | 8.29–8.29% | R400Q (n=13), Y371C (n=2), M234T (n=1), T411I (n=1), T49A (n=1) |
| BCR | — | by frequency | SNV / small indel | 15 / 193 | 7.77% | — | 1 / 1 | 7.77–7.77% | P20S (n=2), G6D (n=2), G124D (n=1), P113S (n=1), E141K (n=1) |
| SGK1 | — | by frequency | SNV / small indel | 14 / 193 | 7.25% | — | 1 / 1 | 7.25–7.25% | X51_splice (n=3), A48V (n=2), X26_splice (n=1), G259V (n=1), F38* (n=1) |
| PIM1 | — | by frequency | SNV / small indel | 14 / 193 | 7.25% | — | 1 / 1 | 7.25–7.25% | S75P (n=2), L80Rfs*7 (n=1), X35_splice (n=1), G28V (n=1), L25V (n=1) |
| SRSF2 | — | by frequency | SNV / small indel | 13 / 193 | 6.74% | — | 1 / 1 | 6.74–6.74% | P95R (n=3), P95_R117del (n=2), G93_H100del (n=1), P95L (n=1), Y92N (n=1) |
| SETD1B | — | by frequency | SNV / small indel | 13 / 193 | 6.74% | — | 1 / 1 | 6.74–6.74% | H8Pfs*30 (n=4), P452Hfs*57 (n=2), K91N (n=1), L1532Ffs*35 (n=1), S1814N (n=1) |
| H1-2 | — | by frequency | SNV / small indel | 13 / 193 | 6.74% | — | 1 / 1 | 6.74–6.74% | A61T (n=2), A171P (n=2), A190T (n=1), S78Rfs*2 (n=1), A101S (n=1) |
| LTB | — | by frequency | SNV / small indel | 12 / 193 | 6.22% | — | 1 / 1 | 6.22–6.22% | L46* (n=2), V36L (n=2), L74* (n=1), X55_splice (n=1), P48A (n=1) |
| CCND3 | — | by frequency | SNV / small indel | 12 / 193 | 6.22% | — | 1 / 1 | 6.22–6.22% | I290K (n=3), R271Pfs*53 (n=2), P284R (n=1), I290R (n=1), I290T (n=1) |
| B2M | — | by frequency | SNV / small indel | 12 / 193 | 6.22% | — | 1 / 1 | 6.22–6.22% | M1? (n=8), L12P (n=2), L43P (n=1), R3Lfs*55 (n=1), X23_splice (n=1) |
| ACTG1 | — | by frequency | SNV / small indel | 12 / 193 | 6.22% | — | 1 / 1 | 6.22–6.22% | S60R (n=3), G13D (n=2), I10T (n=2), G20D (n=1), H73N (n=1) |
| FAT1 | — | by frequency | SNV / small indel | 11 / 193 | 5.7% | — | 1 / 1 | 5.7–5.7% | P4258L (n=1), K2692E (n=1), V3318I (n=1), R1543P (n=1), V2214G (n=1) |
| FAS | — | by frequency | SNV / small indel | 11 / 193 | 5.7% | — | 1 / 1 | 5.7–5.7% | G286E (n=2), M1? (n=2), X218_splice (n=1), K246* (n=1), Q26* (n=1) |
| DTX1 | — | by frequency | SNV / small indel | 10 / 193 | 5.18% | — | 1 / 1 | 5.18–5.18% | Q81R (n=2), G58D (n=2), V70L (n=2), N21I (n=1), *35* (n=1) |
| BTG1 | — | by frequency | SNV / small indel | 9 / 193 | 4.66% | — | 1 / 1 | 4.66–4.66% | L37M (n=2), S43N (n=2), F25S (n=1), L37Q (n=1), Q36H (n=1) |
| HLA-A | — | by frequency | SNV / small indel | 8 / 193 | 4.15% | — | 1 / 1 | 4.15–4.15% | Q78* (n=2), L12Hfs*82 (n=1), Y31* (n=1), L150Q (n=1), L13Pfs*82 (n=1) |
| H1-5 | — | by frequency | SNV / small indel | 8 / 193 | 4.15% | — | 1 / 1 | 4.15–4.15% | P203S (n=2), S92N (n=2), K172T (n=1), A131G (n=1), A177T (n=1) |
| H1-3 | — | by frequency | SNV / small indel | 8 / 193 | 4.15% | — | 1 / 1 | 4.15–4.15% | A102T (n=1), K131R (n=1), G92D (n=1), A191T (n=1), S87N (n=1) |
| EPHA5 | — | by frequency | SNV / small indel | 8 / 193 | 4.15% | — | 1 / 1 | 4.15–4.15% | T944M (n=1), C408R (n=1), A831S (n=1), A890V (n=1), P697Q (n=1) |
| ATP6AP1 | — | by frequency | SNV / small indel | 7 / 193 | 3.63% | — | 1 / 1 | 3.63–3.63% | E346K (n=1), D284G (n=1), S335F (n=1), S305F (n=1), A3Rfs*76 (n=1) |
| ARID5B | — | by frequency | SNV / small indel | 7 / 193 | 3.63% | — | 1 / 1 | 3.63–3.63% | F21L (n=1), S588Vfs*41 (n=1), S71F (n=1), W61* (n=1), X467_splice (n=1) |
Cohorts
Listed in the disease profile, not searched: a name search returns the same patients under several accessions. Patients are unique patient ids in the study's sequenced sample list. Hypermutated: more than ten times the cohort's median non-silent mutations per sample, and at least 100.
| Cohort | Accession | Patients | Samples sequenced / in study | Assay | Panels (samples) | Build | Profiles read | Hypermutated patients | Median mutations / sample |
|---|---|---|---|---|---|---|---|---|---|
| MSK-IMPACT Heme, follicular lymphoma subset (2022) reference | heme_msk_impact_2022 | 193 observed | 213 / 2383 | targeted panel | IMPACT-HEME-400 (213) | hg19 | SNV, small indel, amplification, deep deletion | 0 | 9 |
Copy-number events
Discrete calls from each study's copy-number profile: 2 is high-level amplification, −2 deep deletion. Gains and shallow losses are not counted. Denominators are the cohort's copy-number sample list, which differs from its sequenced list. Rows at 2% or more.
| Gene | Event | Observed patients | Tested patients | Frequency | Cohort | Profile |
|---|---|---|---|---|---|---|
| TNFRSF14 | deep deletion | 22 | 193 | 11.4% | heme_msk_impact_2022 | heme_msk_impact_2022_cna |
| TNFAIP3 | deep deletion | 10 | 193 | 5.18% | heme_msk_impact_2022 | heme_msk_impact_2022_cna |
| FAS | deep deletion | 6 | 193 | 3.11% | heme_msk_impact_2022 | heme_msk_impact_2022_cna |
| CREBBP | deep deletion | 4 | 193 | 2.07% | heme_msk_impact_2022 | heme_msk_impact_2022_cna |
| SOCS1 | deep deletion | 4 | 193 | 2.07% | heme_msk_impact_2022 | heme_msk_impact_2022_cna |
Cohort-aware frequencies
Each row is calculated from unique patients in that study's sequenced sample list. The range is descriptive; no pooled estimate is shown because cross-study overlap and assay comparability have not been checked.
| Gene | Range | Per cohort (altered / tested) |
|---|---|---|
| BCL2 | 34.72–34.72% | heme_msk_impact_2022: 67/193 (34.72%) |
| MS4A1 | null–null% | heme_msk_impact_2022: not assayed |
| CD19 | null–null% | heme_msk_impact_2022: not assayed |
| EZH2 | 20.73–20.73% | heme_msk_impact_2022: 40/193 (20.73%) |
| CREBBP | 70.98–70.98% | heme_msk_impact_2022: 137/193 (70.98%) |
| KMT2D | 66.32–66.32% | heme_msk_impact_2022: 128/193 (66.32%) |
| CD79B | 1.55–1.55% | heme_msk_impact_2022: 3/193 (1.55%) |
| PIK3CD | null–null% | heme_msk_impact_2022: not assayed |
| BTK | 6.22–6.22% | heme_msk_impact_2022: 12/193 (6.22%) |
| CD22 | null–null% | heme_msk_impact_2022: not assayed |
| TNFRSF14 | 46.63–46.63% | heme_msk_impact_2022: 90/193 (46.63%) |
| STAT6 | 20.21–20.21% | heme_msk_impact_2022: 39/193 (20.21%) |
| FOXO1 | 18.13–18.13% | heme_msk_impact_2022: 35/193 (18.13%) |
| SOCS1 | 15.54–15.54% | heme_msk_impact_2022: 30/193 (15.54%) |
| H1-4 | 15.54–15.54% | heme_msk_impact_2022: 30/193 (15.54%) |
| IRF8 | 15.03–15.03% | heme_msk_impact_2022: 29/193 (15.03%) |
| ARID1A | 13.47–13.47% | heme_msk_impact_2022: 26/193 (13.47%) |
| MEF2B | 11.92–11.92% | heme_msk_impact_2022: 23/193 (11.92%) |
| EP300 | 10.88–10.88% | heme_msk_impact_2022: 21/193 (10.88%) |
| CARD11 | 10.88–10.88% | heme_msk_impact_2022: 21/193 (10.88%) |
| TNFAIP3 | 10.36–10.36% | heme_msk_impact_2022: 20/193 (10.36%) |
| GNA13 | 9.84–9.84% | heme_msk_impact_2022: 19/193 (9.84%) |
| TP53 | 9.33–9.33% | heme_msk_impact_2022: 18/193 (9.33%) |
| RRAGC | 9.33–9.33% | heme_msk_impact_2022: 18/193 (9.33%) |
| ATP6V1B2 | 8.29–8.29% | heme_msk_impact_2022: 16/193 (8.29%) |
| BCR | 7.77–7.77% | heme_msk_impact_2022: 15/193 (7.77%) |
| SGK1 | 7.25–7.25% | heme_msk_impact_2022: 14/193 (7.25%) |
| PIM1 | 7.25–7.25% | heme_msk_impact_2022: 14/193 (7.25%) |
| SRSF2 | 6.74–6.74% | heme_msk_impact_2022: 13/193 (6.74%) |
| SETD1B | 6.74–6.74% | heme_msk_impact_2022: 13/193 (6.74%) |
| H1-2 | 6.74–6.74% | heme_msk_impact_2022: 13/193 (6.74%) |
| LTB | 6.22–6.22% | heme_msk_impact_2022: 12/193 (6.22%) |
| CCND3 | 6.22–6.22% | heme_msk_impact_2022: 12/193 (6.22%) |
| B2M | 6.22–6.22% | heme_msk_impact_2022: 12/193 (6.22%) |
| ACTG1 | 6.22–6.22% | heme_msk_impact_2022: 12/193 (6.22%) |
| FAT1 | 5.7–5.7% | heme_msk_impact_2022: 11/193 (5.7%) |
| FAS | 5.7–5.7% | heme_msk_impact_2022: 11/193 (5.7%) |
| DTX1 | 5.18–5.18% | heme_msk_impact_2022: 10/193 (5.18%) |
| BTG1 | 4.66–4.66% | heme_msk_impact_2022: 9/193 (4.66%) |
| HLA-A | 4.15–4.15% | heme_msk_impact_2022: 8/193 (4.15%) |
| H1-5 | 4.15–4.15% | heme_msk_impact_2022: 8/193 (4.15%) |
| H1-3 | 4.15–4.15% | heme_msk_impact_2022: 8/193 (4.15%) |
| EPHA5 | 4.15–4.15% | heme_msk_impact_2022: 8/193 (4.15%) |
| ATP6AP1 | 3.63–3.63% | heme_msk_impact_2022: 7/193 (3.63%) |
| ARID5B | 3.63–3.63% | heme_msk_impact_2022: 7/193 (3.63%) |
What this page does not do
Structural variants
Read the structural-variant profiles the studies carry; fusions are the defining event in several of these diseases.
Context
Stage, subtype, age and treatment line are not attached to any count; the cohorts differ on all four.
Interpretation
Activating versus inactivating, actionable versus not, and evidence level are not inferred here; the briefing's target table carries the drug and trial facts.
Limitations
- A cBioPortal public-API snapshot retrieved 2026-09-26; the page does not refresh source data at request time.
- Counts are patients with at least one non-silent call in the study's sequenced sample list; silent, intronic and UTR calls are excluded.
- For targeted-panel cohorts each gene divides by the patients whose panel carried it; a gene absent from the panel is shown as not assayed, not as zero.
- Copy-number rows use discrete calls (2 = high-level amplification, −2 = deep deletion) against the cohort's copy-number sample list, which is a different roster from the sequenced one.
- Cohorts are not pooled. Cross-study patient overlap has not been checked and no disease-wide frequency is reported.
- Structural variants and fusions are not read in this snapshot even where the study carries a profile; germline variants, mutational signatures, TMB and MSI are not reported.
- The gene set is the briefing's curated targets plus the reference cohort's most frequently mutated genes; it is not genome-wide.
How a machine should read this page
- Denominators: every frequency divides by the patients in one named cohort on whom the gene could be called; there is no disease-wide figure.
- Missing values:
not_assayed(the panel did not carry the gene),not_observed(assayed, none found) andnot_evaluable(the cohort could not be read) are three different facts and are never converted to zero. - Counting: patients, not samples; several samples from one patient count once. Non-silent calls only.
- Copy number: a separate assay with a separate roster; discrete calls at ±2 only.
- Hypermutation: flagged per cohort; the headline keeps all patients and the frequency without them is reported beside it.
- Provenance: every value carries the study id, the retrieval date and the processing version; the source is the cBioPortal public API.
Machine endpoints: full landscape · genes · cohorts · the disease's own facts: /disease/follicular-lymphoma.json.
Built by the BioTransfer briefings pipeline from the cBioPortal public API. The neuroblastoma page was assembled by hand and set the rules this page follows; how these are built.